Posts Feed
Comments Feed

Novel Rapydan(R) Gains Marketing Authorisation In EU For The Relief Of Pain Associated With Needle Puncture And Cannulation

EUSA Pharma announced that RapydanŽ (70 mg lidocaine/70 mg tetracaine medicated plaster) has now received marketing authorisation in Sweden, the UK, Germany, the Netherlands, France, Spain, Austria, the Czech Republic, Greece, Ireland, Norway and Portugal following the completion of the European Mutual Recognition Procedure.

More: continued here

No Comments »

Trackback URI | Comments RSS

Leave a Reply

You must be logged in to post a comment.